Results 21 to 30 of about 3,241 (183)

Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells

Nature Communications, 2022
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and highly aggressive hematologic malignancy derived from the precursors of plasmacytoid dendritic cells.
Tianyu Cai, Agnès Gouble, Kathryn L. Black, Anna Skwarska, Ammar S. Naqvi, Deanne Taylor, Ming Zhao, Qi Yuan, Mayumi Sugita, Qi Zhang, Roman Galetto, Stéphanie Filipe, Antonio Cavazos, Lina Han, Vinitha Kuruvilla, Helen Ma, Connie Weng, Chang-Gong Liu, Xiuping Liu, Sergej Konoplev, Jun Gu, Guilin Tang, Xiaoping Su, Gheath Al-Atrash, Stefan Ciurea, Sattva S. Neelapu, Andrew A. Lane, Hagop Kantarjian, Monica L. Guzman, Naveen Pemmaraju, Julianne Smith, Andrei Thomas-Tikhonenko, Marina Konopleva   +32 more
doaj   +1 more source

Blastic Plasmacytoid Dendritic Cell Neoplasm BPDCN

Hematology, Transfusion and Cell Therapy, 2023
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with an aggressive clinical course and poor prognosis. BPDCN is most often characterized by its presentation with cutaneous lesions which are often asymptomatic, can be
Hanan Hamed
doaj   +1 more source

Blastic Plasmacytoid Dendritic Cell Neoplasm

Current Treatment Options in Oncology, 2019
While there is a high initial response rate with standard chemotherapeutic regimens for blastic plasmacytoid dendritic cell neoplasm (BPDCN), the responses are typically not durable and this remains a very aggressive disease with generally poor outcomes.
Daniel, Kerr, Ling, Zhang, Lubomir, Sokol   +2 more
  +7 more sources

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) arising in the setting of polycythemia vera (PV): An illustration of the emerging role of flow cytometry analysis in monitoring progression of myeloproliferative neoplasms

eJHaem, 2022
This report highlights the value of flow cytometry analysis, particularly in the setting of myeloproliferative neoplasms showing features of progression, as neoplastic plasmacytoid dendritic cell (PDC) proliferations may be present, representing either a
Siba El Hussein, Mariko Yabe, Wei Wang, Naveen Pemmaraju, Sanam Loghavi, Fatima Zahra Jelloul, Hong Fang, L. Jeffrey Medeiros, W. Richard Burack, Andrew G. Evans, Jane L. Liesveld, John M. Bennett   +11 more
doaj   +1 more source

Immunotherapies Targeting CD123 and CD303: A New Frontier in Treating Blastic Plasmacytoid Dendritic Cell Neoplasm. [PDF]

Int J Mol Sci
: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy characterized by the overexpression of CD123 and CD303 surface antigens.
Galati D, Zanotta S, Florio F, Mele S, De Filippi R, Pinto A.   +5 more
europepmc   +3 more sources

MRD IN BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM

Hematology, Transfusion and Cell Therapy, 2022
Objective: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an extremely rare disease with an aggressive course. Plasmacytoid dendritic cells (PDCs) are a component of the innate immune response: they secrete large amounts of type I interferons ...
Aleksandra Palladina, Alexander Popa, Timur Valiev, Nikolay Tupitsyn   +3 more
doaj   +1 more source

Bortezomib as a new therapeutic approach for blastic plasmacytoid dendritic cell neoplasm

Haematologica, 2017
Blastic plasmacytoid dendritic cell neoplasm is an aggressive hematologic malignancy with a poor prognosis. No consensus regarding optimal treatment modalities is currently available. Targeting the nuclear factor-kappa B pathway is considered a promising
Laure Philippe, Adam Ceroi, Elodie Bôle-Richard, Alizée Jenvrin, Sabeha Biichle, Sophie Perrin, Samuel Limat, Francis Bonnefoy, Eric Deconinck, Philippe Saas, Francine Garnache-Ottou, Fanny Angelot-Delettre   +11 more
doaj   +1 more source

Disseminated blastic plasmacytoid dendritic cell neoplasm [PDF]

Blood, 2015
![Figure][1] A 63-year-old man presented with cutaneous nodules. Workup revealed anemia, thrombocytopenia, monocytosis, and 5% circulating “blasts.” Bone marrow sampling showed 33% immature-appearing cells (panel A), with occasional “tadpole” appearance (panel A, lower inset) and ...
Sanam Loghavi, Joseph D. Khoury
openaire   +2 more sources

Tagraxofusp: Expanding Therapeutic Horizons in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) [PDF]

, 2023
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematological malignancy with limited treatment options. The development of tagraxofusp, a CD123-directed recombinant fusion protein, has revolutionized the management of BPDCN.
Dwivedi, Dr sugreev Dwivedi Anuj
core   +2 more sources

Targeted ultra-deep sequencing reveals recurrent and mutually exclusive mutations of cancer genes in blastic plasmacytoid dendritic cell neoplasm [PDF]

, 2014
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare haematopoietic malignancy characterized by dismal prognosis and overall poor therapeutic response. Since the biology of BPDCN is barely understood, our study aims to shed light on the genetic
Anagnostopoulos, Ioannis, Andrulis, Mindaugas, Endris, Volker, Goerdt, Sergij, Hartschuh, Wolfgang, Jöhrens, Korinna, Klapper, Wolfram, Klauschen, Frederick, Koch, Philipp-Sebastian, Lennerz, Jochen K., Pfarr, Nicole, Schulz, Miriam, Siebolts, Udo, Stenzinger, Albrecht, Weichert, Wilko, Wickenhauser, Claudia, Wolf, Thomas   +16 more
core   +1 more source